Target：Integrin β3
Fields：Rap1 signaling pathway;Phagosome;PI3K-Akt signaling pathway;Osteoclast differentiation;Focal adhesion;ECM-receptor interaction;Platelet activation;Neutrophil extracellular trap formation;Hematopoietic cell lineage;Regulation of actin cytoskeleton;Thyroid hormone signaling pathway;Human cytomegalovirus infection;Human papillomavirus infection;Herpes simplex virus 1 infection;Proteoglycans in cancer;MicroRNAs in cancer;Hypertrophic cardiomyopathy;Arrhythmogenic right ventricular cardiomyopathy;Dilated cardiomyopathy;Fluid shear stress and atherosclerosis
Gene Name：ITGB3 GP3A
Protein Name：Integrin beta-3 (Platelet membrane glycoprotein IIIa) (GPIIIa) (CD antigen CD61)
Human Gene Id：3690
Human Swiss Prot No：P05106
Immunogen：Synthesized peptide derived from human CD61 AA range: 1-100
Specificity：The antibody can specifically recognize human CD61 protein.
Formulation：PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA
Source：Mouse, Monoclonal/IgG1, kappa
Dilution：IHC 1:200-400. ELISA 1:500-5000
Purification：The antibody was affinity-purified from ascites by affinity-chromatography using specific immunogen.
Storage Stability：-15°C to -25°C/1 year(Do not lower than -25°C)
Molecular Weight(Da)：87kD
Observed Band(KD)：70kD
Background： The ITGB3 protein product is the integrin beta chain beta 3. Integrins are integral cell-surface proteins composed of an alpha chain and a beta chain. A given chain may combine with multiple partners resulting in different integrins. Integrin beta 3 is found along with the alpha IIb chain in platelets. Integrins are known to participate in cell adhesion as well as cell-surface mediated signalling. [provided by RefSeq, Jul 2008],
Function：disease:Defects in ITGB3 are a cause of Glanzmann thrombasthenia (GT) [MIM:273800]; also known as thrombasthenia of Glanzmann and Naegeli. GT is the most common inherited disease of platelets. Its inheritance is autosomal recessive. It is characterized by mucocutaneous bleeding of mild-to-moderate severity and the inability of this integrin to recognize macromolecular or synthetic peptide ligands. GT has been classified clinically into types I and II. In type I, platelets show absence of the glycoprotein IIb-IIIa complexes at their surface and lack fibrinogen and clot retraction capability. In type II, the platelets express the GPIIb-IIIa complex at reduced levels (5-20% controls), have detectable amounts of fibrinogen, and have low or moderate clot retraction capability. The platelets of GT variants have normal or near normal (60-100%) expression of dysfunctional receptors.,function:Int
Subcellular Location：Cytoplasmic
Expression：Isoform beta-3A and isoform beta-3C are widely expressed. Isoform beta-3A is specifically expressed in osteoblast cells; isoform beta-3C is specifically expressed in prostate and testis.
